Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter s Q4 Revenues Increase 9 Percent

NEW YORK, Jan. 28 (GenomeWeb News) - Beckman Coulter today reported revenues of $694 million for the quarter ending Dec. 31, an increase of 9 percent over $639 million for the year-ago period.

 

Beckman's net earnings for the period were $60 million, down 15 percent from last year's $70 million in the fourth quarter.

 

The company said the drop in its net revenues was a consequence of growing sales of its diagnostic instrument systems, which should result in increased revenue in the future from the consumption of aftermarket test kits, the company said. Beckman did not give a time frame to expect the growth to come.

 

Beckman reported R&D expenditures of $54 million for the quarter, compared to $55 million for the year-ago quarter.

 

The company had cash and cash equivalents of $68 million as of Dec. 31.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.